IRIS
VICECONTE, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.934
EU - Europa 1.263
NA - Nord America 1.140
SA - Sud America 225
AF - Africa 58
OC - Oceania 5
Totale 4.625
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.074
SG - Singapore 950
RU - Federazione Russa 667
CN - Cina 573
IT - Italia 242
BR - Brasile 188
HK - Hong Kong 134
VN - Vietnam 124
DE - Germania 99
NL - Olanda 67
KR - Corea 49
GB - Regno Unito 46
FR - Francia 42
IN - India 35
CA - Canada 31
FI - Finlandia 26
MX - Messico 23
PL - Polonia 19
ZA - Sudafrica 17
AR - Argentina 16
BD - Bangladesh 16
CI - Costa d'Avorio 13
AT - Austria 11
JP - Giappone 10
MA - Marocco 10
SE - Svezia 10
ID - Indonesia 9
EC - Ecuador 8
UA - Ucraina 7
PK - Pakistan 6
EG - Egitto 5
ES - Italia 5
IE - Irlanda 5
IQ - Iraq 5
AZ - Azerbaigian 4
CL - Cile 4
CH - Svizzera 3
CO - Colombia 3
LT - Lituania 3
PH - Filippine 3
SA - Arabia Saudita 3
TR - Turchia 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
JM - Giamaica 2
JO - Giordania 2
MK - Macedonia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
TT - Trinidad e Tobago 2
AO - Angola 1
BE - Belgio 1
BG - Bulgaria 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
DJ - Gibuti 1
HR - Croazia 1
IR - Iran 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
NG - Nigeria 1
PE - Perù 1
PW - Palau 1
PY - Paraguay 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SO - Somalia 1
SV - El Salvador 1
TJ - Tagikistan 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
ZW - Zimbabwe 1
Totale 4.625
Salva come PNG Salva come JPEG
Città #
Singapore 484
Hefei 288
Ashburn 204
Moscow 174
Hong Kong 134
Naples 112
Beijing 110
Los Angeles 75
Chandler 67
Santa Clara 57
Ho Chi Minh City 53
Amsterdam 50
Seoul 48
New York 44
Dallas 31
Munich 30
Hanoi 27
São Paulo 25
The Dalles 21
Redondo Beach 20
Frankfurt am Main 16
Montreal 16
Nuremberg 15
Warsaw 15
Buffalo 14
Millbury 14
Boston 13
Seattle 13
Guangzhou 12
Lawrence 12
Turku 12
Atlanta 11
Des Moines 11
Mexico City 11
Brooklyn 10
Denver 10
Houston 10
Orem 10
Stockholm 10
Tokyo 10
London 9
Rome 9
Boardman 8
Chaozhou 8
Council Bluffs 8
Kochi 8
Milan 8
Rio de Janeiro 8
Casablanca 7
Chicago 7
Helsinki 7
Lappeenranta 7
Querétaro 7
Bologna 6
Chennai 6
Falkenstein 6
Fisciano 6
Johannesburg 6
Phoenix 6
Poplar 6
Dublin 5
Düsseldorf 5
Guarulhos 5
Kronberg 5
Napoli 5
Ottawa 5
Porto Alegre 5
San Francisco 5
Baku 4
Bengaluru 4
Brasília 4
Dhaka 4
Manchester 4
Marseille 4
Paris 4
Toronto 4
Vienna 4
Washington 4
Wilmington 4
Zhengzhou 4
Baghdad 3
Belo Horizonte 3
Belém 3
Bắc Ninh 3
Cairo 3
Cercola 3
Charlotte 3
Da Nang 3
Guayaquil 3
Haiphong 3
Hanover 3
Hyderabad 3
Itajaí 3
Jakarta 3
Minneapolis 3
Nanjing 3
Osasco 3
Redwood City 3
Richmond 3
Secaucus 3
Totale 2.590
Salva come PNG Salva come JPEG
Nome #
Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves 132
Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019 (COVID-19) 130
A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19 128
Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study 128
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study) 127
Diabetes and COVID-19: The potential role of mTOR 122
COVID-19 chest CT and laboratory features of B.1.617.2 (Delta variant) vs B.1.1.7 (Alpha variant) surge: a single center case-control study 118
Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients 118
Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19 113
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 111
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 110
COVID-19 Post-Exposure Evaluation (COPE) Study: Assessing the Role of Socio-Economic Factors in Household SARS-CoV-2 Transmission within Campania Region (Southern Italy) 110
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study 109
Microbiota and hepatitis C virus in the era of direct-acting antiviral agents 108
Appropriateness of antibiotic prescription for targeted therapy of infections caused by multidrug-resistant bacteria: Assessment of the most common improper uses in a tertiary hospital in Southern Italy 108
Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study 107
Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)(BMC Infect Dis., (2024), 24, 1434, 10.1186/s12879-024-10303-5) 106
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 106
Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study 104
Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort) 104
Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience 103
Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort) 103
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy 103
Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience 101
Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma 101
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 100
Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience 98
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab 98
Prevalence of Pneumocystis jirovecii Colonization in Non-Critical Immunocompetent COVID-19 Patients: A Single-Center Prospective Study (JiroCOVID Study) 97
Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease 97
Chest CT in COVID-19 patients: structured vs conventional reporting 97
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review 97
Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series 95
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019 94
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Journal of Neurology, (2022), 269, 6, (3301-3307), 10.1007/s00415-022-11009-x) 94
Home parenteral nutrition in patients with intestinal failure: Possible undetected complications 89
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis 88
Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study 86
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience 82
Long-term oritavancin therapy for shoulder prosthetic joint infection: A case guided by therapeutic drug monitoring (TDM) 78
Management of hepatitis B virus (HBV) infection in multiple sclerosis patients on disease modifying therapies (DMTs) 74
Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature 67
Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program 66
Caspofungin for Primary Antifungal Prophylaxis in Acute Myeloid Leukemia: A Real-Life Study from an Academic Center 63
COVID-19, SARS and MERS: are they closely related? 54
Covid-19 R0: Magic number or conundrum? 53
Pneumocystis jirovecii pneumonia in COVID-19: an overlooked clinical entity—Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19” 43
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany 43
Epidemiology and pathogenesis of fulminant viral hepatitis in pregnant women 40
Totale 4.703
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.005
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.005
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 0 0 0 0 0 3 1 0 5 6 0 0
2021/202297 0 0 0 0 1 8 3 3 0 10 38 34
2022/2023256 14 14 10 8 35 35 12 27 38 48 13 2
2023/2024275 9 40 38 22 32 48 4 27 5 4 31 15
2024/20251.587 35 24 3 20 54 97 139 92 88 191 586 258
2025/20262.431 377 407 454 459 592 142 0 0 0 0 0 0
Totale 4.703